Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 145,369 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Human Immunodeficiency Virus Infection
Interventions: rice bran arabinoxylan compound (RBAC), Placebo; Dietary Supplement
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Multiple Sclerosis, Neuropathic Pain
Interventions: Active tDCS using tDCS device, SHAM tDCS using tDCS device; Device
Lead sponsor: Thorsten Rudroff; Other
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypertension
Interventions: Adherence Intervention, Attention Control; Behavioral · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Respiratory Diseases, Respiratory Failure
Interventions: Lung ultrasound, Clinical exam, Chest x-ray; Diagnostic Test
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: Up to 18 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Cancer
Interventions: Weight Loss Dietary Pattern; Other
Lead sponsor: Colorado State University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 259 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Eating Behavior
Interventions: Multi-Component eHealth Intervention, namely Healthy Online Parental Education (HOPE); Behavioral
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: HIV Infections
Interventions: Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 398 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: Opioid Use Disorder, Opioid Misuse, Chronic Pain
Interventions: TCM, TCM plus COPES; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Little Rock, Arkansas • Aurora, Colorado • West Haven, Connecticut

Conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
Interventions: 111Indium CHX-A; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C, Chronic
Interventions: PEG-rIL-29, Peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: ZymoGenetics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 29
States / cities: Beverly Hills, California • Coronado, California • La Jolla, California + 26 more

Conditions: Plasmodium Falciparum Infection
Interventions: Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain, Malaria challenge; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Triple Negative Breast Cancer
Interventions: Sacituzumab govitecan-hziy (SG), Pembrolizumab, Capecitabine; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 1,514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 188
States / cities: Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 158 more

Conditions: Total Knee Arthroplasty (TKA)
Interventions: Home Strengthening Exercises, Standard Physical Therapy, Preoperative Assessments; Behavioral · Other
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 4
States / cities: Gainesville, Florida

Conditions: Diabetes, Cardiovascular Risk Factor
Interventions: Current Intervention, Delayed Intervention; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Phantom Limb Pain
Interventions: Mirror Therapy; Behavioral
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Urea Cycle Disorders
Interventions: Not listed
Lead sponsor: Mark Batshaw; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 10
States / cities: Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 7 more

Conditions: Psychotic Disorders
Interventions: Electronic Screen + Education (Phase 1), Targeted Provider Education (Phase 1), Community Mobile Engagement (Phase 2), Clinic based Engagement (Phase 2); Other
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years to 30 Years
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Disease, Cardiovascular Diseases
Interventions: Workplace-tailored CDSMP, Chronic Disease Self-Management Program; Behavioral
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2020
U.S. locations: 13
States / cities: Danielsville, Georgia • Moultrie, Georgia • Valdosta, Georgia

Conditions: Prostate Cancer
Interventions: HIFU (Sonablate® 500), Brachytherapy; Device
Lead sponsor: SonaCare Medical; Industry
Eligibility: 40 Years to 75 Years · Male only
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2020
U.S. locations: 6
States / cities: Birmingham, Alabama • Naples, Florida • Myrtle Beach, South Carolina + 3 more

Conditions: Carcinoma, Non-Small-Cell Lung, Mesothelioma
Interventions: LBH589; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Augusta, Georgia • Chicago, Illinois + 1 more

Conditions: Cerebral Adrenoleukodystrophy (CALD)
Interventions: Lenti-D Drug Product (eli-cel); Genetic
Lead sponsor: Genetix Biotherapeutics Inc.; Industry
Eligibility: Up to 17 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts • Minneapolis, Minnesota

Conditions: Eating Disorders
Interventions: Digital Chatbot Program; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Advanced or Metastatic Breast Cancer, Triple Negative Breast Cancer
Interventions: Dinaciclib, Pembrolizumab; Drug
Lead sponsor: Jo Chien; Other
Eligibility: 18 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Hodgkin Lymphoma
Interventions: enzastaurin, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 24
States / cities: Anchorage, Alaska • Los Angeles, California • Orlando, Florida + 21 more

Search by objective public record fields.

The Effect of an Enhanced Rice Bran Nutritional Supplement in HIV

Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis

Tailored Approaches to Improve Medication Adherence

Use of Lung Ultrasound to Diagnose the Etiology of Respiratory Failure in a PICU.

Diet Composition, Weight Control, and Breast Carcinogenesis

Healthy Online Parental Education Project to Increase Fruit and Vegetable Intake and Active Playtime Among Toddlers

Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV

Pain Care at Home to Amplify Function (Pain CHAMP)

111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer

Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection

Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of Three or Five Administrations of GAP3KO Sporozoites

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Total Knee Arthroplasty Biomechanics

Diabetes Prevention Translation: the Healthy Lifestyle Project

Home-based Self-delivered Mirror Therapy for Phantom Limb Pain

Oxidative Stress, Inflammation and Acute Decompensation in Urea Cycle Disorders

Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement

Putting CDSMP to Work

Clinical Study of the Sonablate® 500 to Treat Localized (T1c/T2a) Prostate Cancer

Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

A Study of the Efficacy and Safety of Hematopoietic Stem Cells Transduced With Lenti-D Lentiviral Vector for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

Eating Disorder Chatbot Optimization

Phase 1b Trial of Dinaciclib With Pembrolizumab for Advanced Breast Cancer

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin